![](https://lumicks.com/wp-content/uploads/2021/05/May_2021_press-release-LUMICKS-RCI-Regensburg-Center-for-Interventional-Immunology.png)
In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…
j.yeh26 May 2021